Social Behavior – Page 20

Italian Antitrust Agency Investigates Novartis, Biogen, and Others Over Lucentis Biosimilar

1 year ago talkbio0Tagged Antitrust Probe, Authority, Bioepis, Biogen, Biosimilars, Byooviz, competition, genentech, Italian language, Lucentis, Novartis, Samsung

Italian Competition Authority, Novartis, Biogen, Samsung Bioepis, Genentech, Lucentis, Byooviz, Biosimilar, Antitrust Probe

ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

1 year ago talkbio0Tagged actinium-225, Authority, BlackRock, cancer pipeline, Gastro-enteropancreatic neuroendocrine tumor, Investments, Isotopes, medical radioisotopes, Munich, Qatar, Radiopharmaceuticals, SLC22A18 gene, Technology, Temasek

ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Amarin Names New CEO Aaron Berg Following Patrick Holt’s Resignation

1 year ago talkbio0Tagged Aaron Berg, Amarin, CEO, Holt, Leadership, Patrick, resignation, Transition Mutation

Amarin, CEO, Patrick Holt, Aaron Berg, Resignation, Leadership Transition

Annexon Shares Soar as ANX005 Meets Primary Endpoint in Phase 3 Trial for Guillain-Barré Syndrome

1 year ago talkbio0Tagged Annexon, ANX005, Disability, Guillain-Barre Syndrome, Phase 3 trial, Prices, Primary Endpoint, Sharing (Social Behavior), surge

Annexon, ANX005, Guillain-Barré Syndrome, Phase 3 Trial, Primary Endpoint, Disability Reduction, Share Price Surge

Biogen and Ionis’ ALS Treatment Qalsody Receives European Commission Approval

1 year ago talkbio0Tagged Amyotrophic Lateral Sclerosis, authorization, Biogen, Clinical Trials, Commission, European (ethnic group), Ionis, Qalsody, SOD1, SOD1-ALS

Biogen, Ionis, Qalsody, ALS, European Commission, Marketing Authorization, Rare Disease, SOD1-ALS, Neurofilament, Clinical Trials

Galapagos Partners with Adaptimmune for $665M T-Cell Therapy Collaboration

1 year ago talkbio0Tagged Adaptimmune, biobucks, Collaboration, financing characteristics, Galapagos, Licensing, Melanoma-Associated Antigen 4, next-generation therapy, T-Cell Receptor, T-cell therapy

Galapagos, Adaptimmune, T-cell therapy, MAGE-A4 TCR, Uza-cel, Biobucks collaboration, Licensing deal, Financing, Next-generation therapy

Unlocking Direct-to-Consumer (DTC) Adoption: Leveraging Telehealth Programs for Enhanced Healthcare Access” ###

1 year ago talkbio0Tagged Adoption, clinical networks, Consumer health, Consumption of goods, Direct-to-Consumer, DTC, Health care facility, perspectives, pharma leaders, Policy, Primary Health Care, Reimbursement models, Services, Telemedicine, virtual care platforms

Direct-to-Consumer (DTC) digital health, Telehealth adoption, Virtual care platforms, Clinical networks, Consumer health and pharma leaders, Telemedicine services, Healthcare consumption, Primary care, Reimbursement models, Policy perspectives